Opening the doors to health innovation
We help entrepreneurs and startups with genuine game-changing medical breakthroughs, define and develop their products in an industry where breakthroughs are often viewed as high risk.
We help investors understand and support medical breakthroughs and coach and lead savvy teams.
Michael J. Weickert, PhD
Dr. Weickert has been developing drugs, devices, and startups for more than 30 years. As an experienced startup CEO (5x), he navigated companies from preclinical through Phase 2 clinical development in oncology and anti-infectives. He held C-level roles in 7 additional startups. He has sourced a total of $195 million in investments and partnerships closing Seed, Series A and B, and 2 strategic deals. For 15 years, Dr. Weickert held roles in public companies including Ligand and Nektar where he worked on products from preclinical through Phase 3. He set up an anti-infectives business unit and ran product development, portfolio management and new product planning at Nektar. In public and startups, he has obtained Orphan and Fast Track for oncology and anti-infective products.
Dr. Weickert is currently CEO of two companies with first-in-class products; Pacylex Pharmaceuticals, a clinical-stage oncology startup and Fe Pharmaceuticals, a preclinical stage anti-infectives startup. He also led Portfolio Management, New Product Planning, Product Marketing, Project Management and Product Development at a variety of companies.
Dr. Weickert has a Ph.D. in Genetics from the University of Wisconsin and worked at the National Cancer Institute at NIH before joining industry more than 30 years ago.